Regarding the American Gastroenterological Association Clinical Practice Update on Exocrine Pancreatic Insufficiency
I write in response to the timely and comprehensive American Gastroenterological Association Clinical Practice Update on Exocrine Pancreatic Insufficiency (EPI) to both congratulate the authors on an excellent review and to raise a few points that I believe require clarification.1 There is an omission in this update of a major cause for steatorrhea and EPI in clinical practice, namely therapy with long-acting somatostatin analogs (octreotide or lanreotide) for syndromic and tumor control in patients with neuroendocrine neoplasms.
